Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Neil Stahl sold 8,306 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Neil Stahl also recently made the following trade(s):

  • On Thursday, June 15th, Neil Stahl sold 8,567 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $468.45, for a total value of $4,013,211.15.
  • On Friday, June 2nd, Neil Stahl sold 2,812 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $479.49, for a total value of $1,348,325.88.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 0.27% during midday trading on Monday, hitting $515.91. The stock had a trading volume of 1,172,388 shares. The stock’s 50-day moving average price is $456.19 and its 200 day moving average price is $393.90. The company has a market cap of $54.47 billion, a price-to-earnings ratio of 62.45 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $521.51. Regeneron Pharmaceuticals also was the target of some unusual options trading activity on Friday. Investors bought 1,150 put options on the company. This is an increase of 496% compared to the typical volume of 193 put options.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, beating the Zacks’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. During the same period in the prior year, the company earned $2.57 earnings per share. The firm’s revenue was up 9.8% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post $12.68 earnings per share for the current year.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-evp-neil-stahl-sells-8306-shares/1395060.html.

Hedge funds have recently made changes to their positions in the stock. Korea Investment CORP boosted its stake in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. WFG Advisors LP boosted its stake in shares of Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. Alpha Windward LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Finally, Welch & Forbes LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $211,000. 66.90% of the stock is owned by institutional investors and hedge funds.

REGN has been the subject of several recent analyst reports. Sanford C. Bernstein restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 25th. Canaccord Genuity reiterated a “hold” rating and issued a $375.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, March 30th. Oppenheimer Holdings, Inc. began coverage on Regeneron Pharmaceuticals in a research report on Thursday, March 16th. They issued a “hold” rating for the company. BMO Capital Markets reissued a “hold” rating and issued a $412.00 target price (up from $408.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 28th. Finally, Leerink Swann reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Monday, March 20th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $446.41.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.